Nonclinical pharmacology and toxicology of the first biosimilar insulin glargine drug product (BASAGLAR ® /ABASAGLAR ® ) approved in the European Union-Reference-Cited by-同舟云学术

Nonclinical pharmacology and toxicology of the first biosimilar insulin glargine drug product (BASAGLAR ® /ABASAGLAR ® ) approved in the European Union

Published:2017-08 Issue: Volume:88 Page:56-65
ISSN:0273-2300
Container-title:Regulatory Toxicology and Pharmacology
language:en
Short-container-title:Regulatory Toxicology and Pharmacology

Author:

Byrd Richard A.,Owens Rebecca A.,Blackbourne Jamie L.,Coutant David E.,Farmen Mark W.,Michael M. Dodson^ORCID,Moyers Julie S.,Schultze A. Eric,Sievert Michael K.,Tripathi Niraj K.,Vahle John L.

Funder

Eli Lilly and Company

Publisher

Elsevier BV

Subject

Toxicology,General Medicine

Reference55 articles.

1. Efficacy and safety of LY2963016 insulin glargine compared with insulin glargine (Lantus®) in patients with type 1 diabetes in a randomized controlled trial: the ELEMENT 1 study;Blevins;Diabetes Obes. Metab.,2015

2. Potent inhibitory effects of transplantable rat glucagonomas and insulinomas on the respective endogenous islet cells are associated with pancreatic apoptosis;Blume;J. Clin. Invest,1995

3. Hunger elicited in the rat by a single injection of crystalline bovine insulin;Booth;Physiol. Behav.,1968

4. Comparative subchronic toxicity studies in rats of LY2963016 (LY), an insulin glargine product, with USA-Sourced Lantus® (US-L) and EU-sourced Lantus® (EU-L);Byrd,2014

5. Pathogenesis of type 2 diabetes mellitus;DeFronzo;Med. Clin. North Am.,2004

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Endocrine System;Haschek and Rousseaux' s Handbook of Toxicologic Pathology;2024

2. Efficacy and Cardiovascular Safety of Insulins;Current Drug Safety;2021-06-08

3. Lilly Insulin Glargine Versus Lantus® in Insulin-Naïve and Insulin-Treated Adults with Type 2 Diabetes: A Randomized, Controlled Trial (ELEMENT 5);Diabetes Therapy;2019-01-02

4. Pharmacotherapy of type1 diabetes in children and adolescents: more than insulin?;Therapeutic Advances in Endocrinology and Metabolism;2018-03-19

5. New Insulins, Biosimilars, and Insulin Therapy;Diabetes Technology & Therapeutics;2018-02